Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AAM, DJM, and CB are members of the Clinical Pharmacogenomics Implementation Consortium. CB is supported by the Cumming School of Medicine at the University of Calgary and the Alberta Children’s Hospital Research Institute. MF declares no conflicts. PDA holds the Alberta Innovates Translational Health Chair in Child and Youth Mental Health. KA has acted in a consulting capacity for companies including Roche Diagnostics, Bristol-Myers Squibb and Otsuka Pharmaceuticals Ltd, Otsuka Canada Pharmaceuticals Inc., Lundbeck, and HLS Therapeutics. She has also received research support from companies including Bristol-Myers Squibb and Otsuka Pharmaceuticals, Johnson and Johnson Research and Development, Jannsen Inc. Canada, and Roche Molecular Systems. DJM is coinvestigator in two pharmacogenetic studies where genetic test kits were provided as in-kind contribution by Assurex Health (Myriad Neuroscience) to evaluate feasibility of pharmacogenetic testing in clinical practice and potential benefits of pharmacogenetic testing compared to treatment as usual. DJM have not received any payments or received any equity, stocks, or options from this company or any other pharmacogenetic companies. DJM is coinvestigator in two filed genetic patents assessing risk of antipsychotic-induced weight gain. CB has received material support from Assurex Health (Myriad Neuroscience), CNSDose, Genomind, and AB-Biotics for research purposes and has ongoing research collaborations with CNSDose and MyDNA but does not have equity, stocks, or options in these companies or any other pharmacogenetic companies. CB, DJM and KA are members of the Genetic Testing Committee of the International Society of Psychiatric Genetics.